Wilson Disease

Slide 1 · Wilson Disease

Inherited disorder of copper metabolism

Molecular pathogenesis • Liver pathology • Clinical diagnosis

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Trace normal copper absorption, hepatocyte handling, and biliary elimination.

Explain how ATP7B dysfunction causes tissue injury and systemic copper deposition.

Recognize the spectrum of hepatic, neurologic, and ocular manifestations.

Integrate biochemical, tissue, ophthalmic, and genetic diagnostic evidence.

Relate copper-directed therapy and transplantation to the underlying defect.

Slide 3 · Wilson disease among inherited liver disorders

Inherited metabolic disorders

Wilson disease: Disturbed copper transport

Hemochromatosis: Excess iron handling

α₁-antitrypsin deficiency: Abnormal protein folding

Distinctive Wilson phenotype

Copper accumulation in hepatocytes

Secondary injury to brain and eye

Mixed hepatic and neurologic presentations

Slide 4 · Core definition

Autosomal recessive loss of ATP7B function

Impaired biliary copper excretion and ceruloplasmin loading produce toxic copper retention.

Slide 5 · Three principal tissue targets

Liver

Intracellular copper

→ inflammation, injury, fibrosis

Brain

Basal ganglia injury

→ movement and other neurologic symptoms

Eye

Descemet membrane copper

→ Kayser–Fleischer ring

Slide 6 · Copper homeostasis depends on the liver

Dietary copper is absorbed from the gastrointestinal tract.

Portal delivery makes hepatocytes central to copper handling.

Copper is partitioned into circulating ceruloplasmin or a biliary elimination pathway.

Failure of hepatic transport can simultaneously reduce circulating ceruloplasmin and raise tissue copper.

Slide 7 · Intestinal copper entry and transfer

Dietary copper

Enterocyte uptake

(CMT1)

ATP7A-mediated

Export

Portal circulation

The intestinal step delivers copper to the liver; Wilson disease is primarily a hepatic ATP7B defect.

Slide 8 · Portal blood transports newly absorbed copper

From intestine to liver

Copper reaches portal circulation after enterocyte export.

Albumin associates with copper in the blood.

Hepatocytes subsequently take up circulating copper.

Why this matters

The liver receives copper before its systemic distribution.

Normal handling prevents excessive unbound copper from accumulating.

Excretion and incorporation regulate the circulating pool.

Slide 9 · Hepatocyte copper uptake

Portal blood

Copper

Hepatocyte

Entry (CMT1)

Intracellular

Copper pool

Copper entering the hepatocyte must be handled by cellular transport and elimination pathways.

Slide 10 · Two physiologic destinations of hepatic copper

Secretory destination

Transport toward the trans-Golgi network

Incorporation into apoceruloplasmin

Secretion of ceruloplasmin into blood

Excretory destination

Intracellular sequestration in lysosomes

Delivery toward canalicular bile

Elimination in feces

Slide 11 · ATP7B coordinates hepatocyte copper handling

HEPATOCYTE — conceptual compartment schematic

Trans-Golgi network

Ceruloplasmin loading

Lysosomal copper

→ bile

Copper uptake

From portal blood

ATP7B enables copper processing and biliary elimination

Slide 12 · The trans-Golgi pathway loads ceruloplasmin

Cytosolic

Copper

ATP7B-associated

TGN transport

Apoceruloplasmin

Loading

Ceruloplasmin

Secretion

Ceruloplasmin forms when copper is incorporated into apoceruloplasmin.

Slide 13 · Biliary copper elimination

Hepatic

Copper pool

Lysosomal

Sequestration

Canalicular

Transport

Bile → feces

The biliary pathway is essential for disposing of copper not routed into ceruloplasmin.

Slide 14 · Ceruloplasmin carries most plasma copper

The textbook attributes approximately 90–95% of plasma copper to ceruloplasmin.

It is produced following copper incorporation into apoceruloplasmin.

A reduced ceruloplasmin pool can lower total measured serum copper.

Total circulating copper and toxic free-copper burden are therefore different concepts.

Slide 15 · Normal handling versus ATP7B dysfunction

Functional ATP7B

Copper incorporation into ceruloplasmin proceeds.

Copper can be excreted into bile.

Hepatocyte copper retention is limited.

ATP7B loss of function

Ceruloplasmin loading and secretion fall.

Biliary copper transport is impaired.

Copper progressively accumulates in hepatocytes.

Slide 16 · Autosomal recessive inheritance

Disease arises from pathogenic changes affecting both ATP7B alleles.

ATP7B encodes a transmembrane, copper-transporting ATPase.

Normal hepatic transport requires sufficient ATP7B function.

Inherited susceptibility is present before overt clinical injury.

Slide 17 · Compound heterozygosity is common

Genotype organization

Patients may carry different ATP7B mutations on the two alleles.

This is termed compound heterozygosity.

Both alleles can contribute to deficient ATP7B function.

Implication for molecular testing

A single detected variant may not establish the biallelic disease genotype.

Variant pathogenicity matters, not merely variant presence.

Clinical and biochemical findings remain relevant.

Slide 18 · Not every ATP7B sequence variant is pathogenic

Sequence variation ≠ confirmed disease mechanism

More than 300 identified variants but explicitly notes that not all cause Wilson disease.

Slide 19 · Frequency estimates

Measure

Robbins 11th-edition estimate

Interpretation

Mutated ATP7B allele frequency

Approximately 1:100

Allele frequency, not disease prevalence

Disease prevalence

Approximately 1:30,000–1:50,000

Population-level estimate

Approximate U.S. patient number

About 9,000

Book estimate; not a live registry count

Slide 20 · Two primary consequences of ATP7B deficiency

Loss of ATP7B activity

Less copper

Into bile

Less copper

Into ceruloplasmin

Copper retention

In hepatocytes

Progressive cellular and systemic toxicity

Slide 21 · Defective biliary excretion drives retention

ATP7B

Loss of function

Reduced copper

Biliary transport

Hepatocyte

Copper accumulation

Toxic liver

Injury

Failure of excretion is central: The body cannot eliminate the accumulating hepatic copper efficiently.

Slide 22 · Defective ceruloplasmin loading alters blood tests

ATP7B

Loss of function

Reduced copper

Incorporation

Lower ceruloplasmin

Secretion

Lower serum

Ceruloplasmin

Serum ceruloplasmin falls for a mechanistic reason; The test indirectly reflects impaired hepatic processing.

Slide 23 · Total serum copper may be misleading

Serum total copper

Includes the large ceruloplasmin-bound fraction.

May be reduced when circulating ceruloplasmin is depleted.

A low value does not exclude toxic tissue copper accumulation.

Tissue or nonceruloplasmin copper

Hepatocyte stores rise during impaired elimination.

Copper escapes injured hepatocytes into blood.

Free copper can exert systemic toxicity.

Slide 24 · The hepatic copper paradox

HEPATOCYTE — conceptual compartment schematic

Trans-Golgi network

Ceruloplasmin loading

Lysosomal copper

→ bile

Copper retention

↑ intracellular copper

ATP7B loss of function → both exit pathways impaired

Slide 25 · Copper promotes free-radical injury

Excess copper

Redox cycling /

Fenton-type reactions

Reactive oxygen

Species

Cellular injury

Copper catalyzes oxidative chemistry that can damage hepatocyte macromolecules.

Slide 26 · Copper binds sulfhydryl groups

Excess intracellular

Copper

Binding to protein

–SH groups

Perturbed protein

Function

Hepatocyte injury

Interaction with sulfhydryl-bearing proteins is a second mechanism of copper toxicity.

Slide 27 · Copper disrupts hepatic metalloenzymes

Excess copper

Displacement of other

Metals

Metalloenzyme

Dysfunction

Cellular stress

The result is loss of normal enzyme function rather than only copper-induced oxidation.

Slide 28 · Three parallel routes to hepatocyte damage

Intracellular copper overload

Free radicals /

Fenton chemistry

Binding protein

Sulfhydryl groups

Metal displacement

In metalloenzymes

Necroinflammation and progressive liver injury

Slide 29 · Damaged hepatocytes redistribute copper

Hepatic copper

Accumulation

Hepatocyte

Injury

Copper spills into

Circulation

Deposition outside

The liver

Organ-specific injury emerges after the primary defect in hepatocyte copper handling.

Slide 30 · Urinary copper increases but does not rescue balance

Renal handling

Excess circulating nonceruloplasmin copper is excreted in urine.

The increase can be marked.

Urinary excretion is diagnostically informative.

Insufficient compensation

The kidney cannot fully prevent tissue deposition.

Hepatic biliary clearance remains impaired.

Copper continues to accumulate in susceptible organs.

Slide 31 · Why the brain and cornea are affected

Liver

Intracellular copper

→ inflammation, injury, fibrosis

Brain

Basal ganglia injury

→ movement and other neurologic symptoms

Eye

Descemet membrane copper

→ Kayser–Fleischer ring

Slide 32 · A staged model of Wilson disease pathogenesis

1. Inherited ATP7B loss of function

2. Impaired copper secretion and biliary elimination

3. Hepatic copper retention and tissue injury

4. Copper redistribution with multi-organ manifestations

Slide 33 · Hepatic morphology spans a broad spectrum

Morphologic pattern

Mild fatty change ± focal hepatocyte necrosis

Acute massive injury / acute liver failure

Chronic hepatitis with steatohepatitis-like injury

End-stage cirrhosis

Interpretive caution

No single morphology is pathognomonic.

Several patterns mimic other common hepatitides.

Interpret histology together with copper studies.

Slide 34 · Steatosis may be an early hepatic manifestation

Fatty change is part of the described Wilson disease spectrum.

Steatosis can coexist with focal hepatocyte necrosis.

Its presence alone cannot establish the diagnosis.

Copper accumulation provides etiologic context for an otherwise nonspecific morphology.

Slide 35 · Focal hepatocyte necrosis marks cell injury

Morphologic finding

Scattered necrotic hepatocytes may accompany steatosis.

Necrosis reflects injury to hepatocytes.

Its extent varies markedly among patients.

Mechanistic linkage

Copper-mediated free-radical generation

Copper-protein and metalloenzyme interactions

These mechanisms provide biological reasons for cell injury.

Slide 36 · Acute liver failure can resemble viral hepatitis

Wilson-related acute presentation

Acute severe hepatocellular injury

Potential clinical picture of liver failure

Etiology: Impaired inherited copper handling

Acute viral hepatitis

Potentially similar acute injury pattern

Clinical and morphologic overlap

Etiology requires other evidence

Slide 37 · Chronic hepatitis includes portal inflammation

Chronic Wilson disease can show moderate-to-severe portal inflammation.

Inflammation occurs in the setting of hepatocellular copper toxicity.

Associated hepatocyte necrosis can be prominent.

The pattern is not sufficiently specific without disease-directed workup.

Slide 38 · Chronic hepatitis may mix injury patterns

Component

Described Wilson-associated finding

Why it matters

Necroinflammatory

Portal inflammation and hepatocyte necrosis

Can resemble chronic hepatitis

Fatty

Hepatocellular steatosis

Can resemble steatotic liver disease

Steatohepatitic

Ballooning and Mallory hyaline

Can suggest other causes of steatohepatitis

Fibrosing

Perisinusoidal fibrosis → cirrhosis

Supports chronic progressive injury

Slide 39 · Ballooned hepatocytes reflect steatohepatitic injury

Reported morphology

Hepatocyte ballooning is described in chronic Wilson disease.

It may coexist with fat and inflammation.

The finding reflects hepatocellular injury.

Diagnostic caution

Ballooning is not specific to Wilson disease.

A steatohepatitic pattern must not automatically be assigned a metabolic or alcohol-associated cause.

Consider etiology across clinical and laboratory data.

Slide 40 · Mallory hyaline occurs in Wilson disease

Prominent Mallory hyaline in some chronic cases.

Its coexistence with ballooning produces a steatohepatitis-like pattern.

Mallory hyaline is not uniquely associated with alcohol-related injury.

Pathogenetic interpretation requires the broader copper-metabolism context.

Slide 41 · Perisinusoidal fibrosis shows chronic progression

Persistent copper

Toxicity

Chronic hepatocyte

Injury

Perisinusoidal

Fibrosis

Architectural

Remodeling

Fibrosis indicates a sustained process rather than isolated acute cytotoxicity.

Slide 42 · Cirrhosis is an advanced hepatic outcome

1. Variable early injury: Steatosis and necrosis

2. Chronic portal inflammation and steatohepatitic change

3. Progressive fibrosis of hepatic parenchyma

4. Cirrhosis and potentially serious hepatic dysfunction

Slide 43 · Copper staining has diagnostic limitations

Histochemical copper stain is neither sensitive nor specific

A positive stain alone does not prove Wilson disease; A negative stain does not exclude it.

Slide 44 · Histopathologic diagnosis requires etiologic correlation

What a liver biopsy can show

Steatosis, necrosis, chronic hepatitis

Ballooning, Mallory hyaline, fibrosis

Potential cirrhotic architecture

What routine morphology cannot alone prove

An ATP7B-associated metabolic defect

Specificity of a steatohepatitic pattern

A definitive Wilson diagnosis without biochemical or other correlation

Slide 45 · Clinical onset is variable

Feature

Description in Robbins

Reported onset range

6–40 years

Reported mean age

11.4 years

Presentations

Liver disease, movement disorder, psychiatric symptoms, or hemolysis

Clinical expression

Extremely variable across patients

Slide 46 · Hepatic and neurologic presentations may diverge

Hepatic-dominant presentation

Acute liver disease

Chronic liver disease

Fatty change, hepatitis, or cirrhosis

Neurologic-dominant presentation

Movement abnormalities

Rigid dystonia or coordination impairment

Often Kayser–Fleischer rings

Slide 47 · Basal ganglia injury explains movement disorders

Hepatocyte

Injury

Circulating copper

Redistribution

Basal ganglia

Copper accumulation

Motor-system

Manifestations

The primary metabolic defect is hepatic, but clinical disability may be neurological.

Slide 48 · Movement-disorder phenotypes are heterogeneous

Phenotype

Clinical manifestations described

Tremor

Involuntary rhythmic movement

Coordination deficit

Poor coordination

Hyperkinetic

Chorea or choreoathetosis

Dystonic / rigid

Spastic dystonia, rigidity and abnormal gait

Slide 49 · Rigid dystonia can dominate the presentation

Spastic dystonia can produce persistent abnormal postures and stiffness.

Masklike facies and generalized rigidity are described.

Gait disturbance can be a prominent sign.

Copper toxicity in basal ganglia links these signs with the systemic disorder.

Slide 50 · Psychiatric symptoms are part of the phenotype

The source explicitly includes psychiatric manifestations.

Neuropsychiatric features may accompany or complicate motor symptoms.

Recognition requires thinking beyond isolated hepatology.

A compatible hepatic or ocular finding changes diagnostic suspicion.

Slide 51 · Kayser–Fleischer ring: Anatomy and appearance

Anatomical localization

Peripheral cornea / limbus

Copper in Descemet membrane

Green-to-brown corneal ring

Schematic—not a clinical slit-lamp photograph

Slide 52 · Kayser–Fleischer ring is especially linked to neurologic disease

Green-to-brown copper deposits form at the corneal limbus.

The copper accumulates within Descemet membrane.

Rings in nearly all patients with neurologic involvement.

Slit-lamp examination makes the finding diagnostically useful.

Slide 53 · Hemolytic anemia results from oxidant injury

Excess free copper

In blood

Oxidant injury

To red cells

Red-cell membrane

Damage

Hemolytic

Anemia

Copper-related hemolysis illustrates extrahepatic toxicity without direct hepatic histologic involvement.

Slide 54 · Diagnostic assessment integrates several domains

Domain

Evidence sought

Purpose

Serum biochemical

Decreased ceruloplasmin

Indirect marker of defective hepatic loading

Tissue copper

Increased hepatic copper content

Direct tissue-burden assessment

Renal excretion

Increased urinary copper

Evidence of excess mobile copper

Ophthalmic

Kayser–Fleischer ring

Accessible extrahepatic deposition sign

Genetic

ATP7B sequencing

Clarify indeterminate biochemical cases

Slide 55 · Serum ceruloplasmin: Useful but not definitive

What a low level supports

ATP7B-dependent copper incorporation is impaired.

Hepatic secretion of ceruloplasmin decreases.

Compatible evidence for Wilson disease.

Why a normal level cannot safely exclude it

Liver injury may raise serum ceruloplasmin.

Clinical context can confound the biochemical result.

Other diagnostic modalities may be needed.

Slide 56 · Hepatic copper content measures tissue accumulation

Liver copper content interrogates the primary site of metal retention.

Increased hepatic content as its most sensitive and accurate test.

A tissue value must be interpreted in the diagnostic context.

No unverified numeric threshold is assumed in this source-based lecture.

Slide 57 · Urinary copper reflects excess circulating copper

Hepatocellular injury increases nonceruloplasmin-bound circulating copper.

Urinary copper excretion rises substantially.

The textbook calls increased urinary copper its most specific test.

Excretion is still insufficient to prevent multi-organ deposition.

Slide 58 · Slit-lamp examination provides visual evidence

Suspected Wilson

Disease

Slit-lamp

Examination

Peripheral corneal

Copper deposits

Diagnostic

Corroboration

A ring supports the diagnosis, particularly when neurologic involvement is present.

Slide 59 · ATP7B sequencing is a resolving test

When to consider sequencing

Biochemical tests are indeterminate.

Ceruloplasmin may be altered by intercurrent liver injury.

Genetic evidence can help resolve the diagnosis.

How to interpret sequencing

Pathogenicity is not guaranteed by any sequence change.

Compound heterozygosity is common.

Genotype should be read with clinical and biochemical phenotype.

Slide 60 · Diagnostic pitfalls are predictable

Pitfall

Why it occurs

Safer interpretation

Low total serum copper

Reduced ceruloplasmin-bound fraction

Do not equate with absence of tissue copper

Normal ceruloplasmin

May rise in the setting of liver injury

Avoid single-test exclusion

Nonspecific hepatic histology

Overlaps viral and steatotic disorders

Correlate with copper studies

Copper stain negative

Histochemical stain lacks sensitivity

Do not exclude on stain alone

Slide 61 · Source-based diagnostic reasoning sequence

Clinical pattern

Raises suspicion

Ceruloplasmin, tissue

& urinary copper

Slit-lamp

Corroboration

ATP7B sequencing

If indeterminate

The sequence is a teaching synthesis, not a formal diagnostic scoring system or published guideline.

Slide 62 · Treatment targets copper burden or entry

Chelator strategy

D-penicillamine or trientine

Long-term drug-based copper reduction

Targets excessive copper burden

Zinc strategy

Reduces uptake of dietary copper in intestine

Limits addition of newly absorbed copper

Targets intestinal copper entry

Slide 63 · Copper chelation interrupts progressive toxicity

Toxic copper

Accumulation

Copper chelation

Therapy

Reduction of excess

Copper burden

Less ongoing

Toxic exposure

Early recognition and sustained therapy are emphasized.

Slide 64 · Zinc decreases intestinal copper uptake

Dietary copper

In intestine

Zinc-based

Therapy

Reduced intestinal

Copper uptake

Less copper

Delivered to liver

This contrasts with chelation: Zinc addresses incoming copper rather than only existing burden.

Slide 65 · Transplantation can correct hepatic transport

Severe hepatic

Disease

Liver

Transplantation

Functional graft

ATP7B handling

Restored hepatic

Copper regulation

Transplantation as potentially curative in severe disease.

Slide 66 · Clinical application: Unexplained hepatic injury

HYPOTHETICAL TEACHING SCENARIO

An adolescent develops persistent hepatocellular injury with steatosis and features of chronic hepatitis. The history does not identify a clear acquired cause.

Which inherited transport disorder belongs in the differential, and why can histology alone be insufficient?

Slide 67 · Case discussion: Liver pathology

Reasoning from the morphology

Wilson disease should be considered as an inherited copper-transport disorder.

Steatosis, portal inflammation, necrosis, and steatohepatitic change are overlapping patterns.

Biochemical copper studies and additional clinical evidence are needed.

Slide 68 · Clinical application: Extrapyramidal presentation

HYPOTHETICAL TEACHING SCENARIO

A young patient has tremor, rigidity, gait difficulty, and a peripheral green-brown corneal ring on ophthalmic examination.

Where is copper depositing, and which metabolic defect unifies the neurologic and ocular findings?

Slide 69 · Case discussion: Systemic copper deposition

The unifying mechanism

Loss of ATP7B prevents effective hepatic copper processing and biliary elimination.

Injured hepatocytes release copper into the circulation.

Copper accumulates in basal ganglia and Descemet membrane, producing the findings.

Slide 70 · Five high-yield conclusions

ATP7B dysfunction creates two defects: Reduced biliary excretion and reduced ceruloplasmin loading.

Copper injures hepatocytes through oxidants, thiol interactions, and metalloenzyme disruption.

Hepatic morphology is broad and can imitate viral or steatohepatitic disease.

Neurologic movement disorders, corneal rings, and hemolysis reflect extrahepatic toxicity.

Diagnosis is integrative; Chelation, zinc, and transplantation address different aspects of disease.

Slide 71 · Primary reference and source boundaries

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026).

Wilson Disease, within Liver and Gallbladder: disease text, morphology, clinical features.

Copper metabolism and ATP7B transport mechanism: accompanying textbook figure caption.

No chapter PDF or licensed histopathology micrographs were supplied; diagrams are editable original teaching schematics.

Diagnostic numerical cutoffs, drug doses, and current guideline algorithms are intentionally not introduced.